Gaston Picchio - Articles and news items

Janssen Pharmaceuticals Logo

Janssen submits supplemental New Drug Application to U.S. FDA for OLYSIO™ for once-daily use in combination with Sofosbuvir for 12 weeks for the treatment of adult patients with genotype 1 chronic hepatitis C

Industry news / 8 May 2014 / Johnson & Johnson

Filing Includes data from treatment-naïve patients with advanced fibrosis and null responders with all stages of liver fibrosis…

Janssen Pharmaceuticals Logo

Incivo®(Telaprevir) data to be presented at AASLD and ISPOR on the anit-viral response, safety, tolerability and cost-effectiveness of an Incivo based regimen in the treatment of genotype-1 chronic hepatitis C

Industry news / 1 November 2013 / Janssen

Janssen continues to undertake clinical studies with telaprevir to identify opportunities to serve specialized and hard-to-treat patients…

Janssen-Cilag International NV Logo

Janssen acquires investigational NS5A inhibitor for the treatment of Hepatitis C from GlaxoSmithKline

Industry news / 8 October 2013 / Janssen Pharmaceuticals, Inc

“We’re excited to add GSK2336805 to our existing portfolio of direct-acting antivirals (DAAs)…

Janssen Pharmaceuticals Logo

INCIVO® (telaprevir) receives European Commission approval

Industry news, News / 31 May 2013 / Daniel J Edelman Ltd

The EC has approved a new twice daily dosing of INCIVO® (telaprevir)…

Janssen Pharmaceuticals Logo

U.S. FDA grants Priority Review to simeprevir for combination treatment of genotype 1 chronic hepatitis C

Industry news, News / 13 May 2013 / Johnson & Johnson

The U.S. FDA has granted Priority Review to the NDA for simeprevir (TMC435)…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...